Viracta Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Director Ivor Royston of Viracta Therapeutics acquired 25,219 shares of common stock through the vesting of restricted stock units.
Director Roger Pomerantz acquired 9,034 shares of Viracta Therapeutics common stock through the vesting of restricted stock units.
Director Ivor Royston of Viracta Therapeutics reports the vesting of restricted stock units and subsequent disposal of common stock.
Director Roger Pomerantz reports changes in beneficial ownership of Viracta Therapeutics stock following the exercise of restricted stock units.
Director Ivor Royston acquired 50,000 stock options in Viracta Therapeutics, Inc. on June 20, 2024.
Flavia Borellini, a director of Viracta Therapeutics, acquired stock options for 50,000 shares at an exercise price of $0.569 on June 20, 2024.
Director Jane Chung acquired 50,000 stock options in Viracta Therapeutics, Inc. on June 20, 2024, according to a Form 4 filing.
Director Samuel Murphy acquired 50,000 stock options in Viracta Therapeutics, Inc. on June 20, 2024, at an exercise price of $0.569.
Director Thomas E. Darcy acquired stock options in Viracta Therapeutics, Inc. on June 20, 2024.
Director Barry J. Simon acquired 50,000 stock options in Viracta Therapeutics, Inc. on June 20, 2024, according to a recent SEC filing.
Jane F. Barlow, a director of Viracta Therapeutics, acquired stock options for 50,000 shares at an exercise price of $0.569 on June 20, 2024.
Director Roger Pomerantz acquired stock options in Viracta Therapeutics, Inc. on June 20, 2024.
Stephen Rubino, a director of Viracta Therapeutics, acquired 50,000 stock options on June 20, 2024, exercisable at $0.569 per share.
Director Roger Pomerantz reports the disposition of 9,035 common stock shares to satisfy vesting restricted stock units.
Director Ivor Royston of Viracta Therapeutics reports the acquisition and disposal of common stock and vesting of restricted stock units.
Michael E. Faerm, CFO of Viracta Therapeutics, acquired 500,000 stock options on May 14, 2024, according to a Form 4 filing with the SEC.
Viracta Therapeutics CEO, Mark Rothera, reports the acquisition of 475,000 stock options on March 12, 2024.
Darrel P. Cohen, Chief Medical Officer of Viracta Therapeutics, acquired 120,000 stock options on March 12, 2024, at an exercise price of $0.985.
Daniel Chevallard, CFO and COO of Viracta Therapeutics, acquired 200,000 stock options on March 12, 2024, according to a Form 4 filing with the SEC.
Director Ivor Royston of Viracta Therapeutics reports the vesting of restricted stock units and subsequent ownership changes.
Director Roger Pomerantz exercised restricted stock units (RSUs) for Viracta Therapeutics common stock on February 25, 2024.
Daniel Chevallard, CFO and COO of Viracta Therapeutics, reports the acquisition and disposal of common stock and restricted stock units to cover tax obligations.